ASX Announcement

12 November 2020

POST AGM UPDATE - PRESENTATION

AnteoTech Limited (ASX: ADO) ('**AnteoTech**' or '**the Company**') is pleased to attach a presentation to be made by Chief Executive Officer Derek Thomson at a post AGM webinar.

The webinar will be held on Thursday, November 12, 2020 at 10.30am AEST to provide an update on the Company's operations.

Derek will be on hand to address any questions during the presentation. Participants will be invited by the moderator to ask questions directly via the online forum.

Anyone wishing to attend the Post AGM Update needs to register using the link below.

Webinar details:
Date and time: Thursday, November 12 at 10.30 am AEST (11.30am AEDT Sydney; 8.30 am AWST Perth/Hong Kong)

Register: https://vep.express.vc/register/?event_id=4cf90b88-00ec-432a-8a30-5b85e1b89085

Replay: Available on the AnteoTech website and social media following the broadcast.

This announcement has been approved by the Board.

For more information, please contact:
Derek Thomson, Chief Executive Officer, AnteoTech Ltd: +61 (0) 7 3219 0085
Ben Jarvis, Six Degrees Investor Relations: +61 (0) 413 150 448
Follow AnteoTech on Twitter:

https://twitter.com/AnteoTech_ or visit www.anteotech.com

AGM Business Update

Derek Thomson – CEO

12th November 2020

Disclaimer

The purpose of the presentation is to provide an update of the business of AnteoTech Ltd (ASX:ADO). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by AnteoTech and should not be relied upon as an independent source of information. Please contact AnteoTech and/or refer to the Company's website for further information.

The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information.

Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside AnteoTech Ltd's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks. Because actual results could differ materially to assumptions made and AnteoTech's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution.

This presentation should not be relied on as a recommendation or forecast by AnteoTech Ltd. Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

Agenda

- **Business Overview**
- **Life Sciences**
  - Market Outlook
  - Achievements
  - COVID-19 Rapid Antigen Test Update
  - Focus for Next Twelve Months
- **Questions**
- **Energy**
  - Market Outlook
  - Energy Strategy
  - Collaborator Network
  - Achievements
  - Development Program
- **Focus for Next 12 Months**
- **Questions**

Business Dashboard

Revenues Rising

Opportunity Pipeline Increasing

Addressable Markets Growing



Good Cash Position

IP Position Strengthened

Development Teams Expanded and Operating at Full Capacity

AnteoTech

Life Sciences

Lateral Flow Market (LFA)

- The global lateral flow assay market was projected to reach USD 8.7 billion by 2023 from USD 7.0 billion in 2019 growing at a CAGR of 7.7% from 2019 to 2023.
- However the impact of COVID-19 will alter the profile of the market significantly in the next 5 years.
- We have seen reports that suggest the LFA market will rise very significantly in the short term due to high rate of demand for COVID-19 LFIA test globally.
- This trend is supported by a significant ramp up in investment in manufacturing capability for LFIA test specifically focused on COVID-19 in major markets.
- We believe that market acceleration will continue even with the introduction of a vaccine for at least 3 years.



Source: "Lateral Flow Assay Market by Application,Product, Technique, End User - Global Forecast to 2023" report from ResearchAndMarkets.com

Life Sciences
Key Achievements in 2020

- ISO 13485 certification
- Completed Proof of Concept Assay for Detection of Sepsis.
- Raw Materials Sales Increase.
- Completed first OEM AnteoBind™ Activated Particle set of products with IMRA.
- Developed Proof of Concept COVID-19 Antigen Rapid Test* and progressing to clinical trials followed by commercialisation if successful.
- Successfully trialed Proof of Concept COVID-19 / Flu A/B Multiplex Test.
- Established a position in the vaccine industry for efficient QC testing.
- Foundation for Assay Services business established.

*The AnteoTech Antigen Rapid Test detects the Sars-Cov-2 active virus that causes the disease called COVID-19.



Our Assay Development Differentiator is Very High Sensitivity Detection

- Consistent gentle binding proven to retain antibody activity.
- Simple conjugation.
- The only COVID-19 Antigen Rapid Test using AnteoBind™ activated Europium.

- Proven activated particle stable in storage for up to 1 year.



- Very high dynamic signal range and intensity.
- Consistent and reliable results under UV light.
- Can be used for quantitative detection.
- Improves LLOD range.

- Easy scale-up improves manufacturability and batch-to-batch consistency.

Delivery of the AnteoTech COVID-19 Antigen Rapid Test is On Track

Time frame: 3-5 months

Phase 1: Feasibility

Phase 2: Design Verification

Phase 3: Design Validation

Phase 4: Production Validation

Phase 5: Market Launch

- **Phase 1- Completed:** Feasibility (demonstrated working prototypes for COVID-19 antigen assays).
- **Phase 2 - Completed:** Design verification (design inputs).
- **Phase 3 - In progress:** Design validation (design review and freeze, Clinical Trials).
- **Phase 4 -About to begin**: Final design produced at manufacturing site. Tech transfer and contract manufacturing scale up.
- **Phase 5 - 1st Qtr (Jan – March) 2021**: Regulatory approval process, distribution and marketing arrangements finalised.



The Next Twelve Months will be very Productive for our Life Sciences Business

Assay Development

- Completion of COVID-19 Antigen Rapid Test.
- Extend the COVID-19 Antigen use case to saliva sampling.
- Complete commercialisation of COVID-19 Flu A Flu B multiplex test.
- Commercialise Sepsis test.
- Analyse market opportunities for rapid tests where there is clinical need.
- Start new rapid test projects.

Raw Materials

- Focus and investment on customer knowledge and problem sets.
- Particular focus on the vaccine industry and issues on safe development and distribution
- Use knowledge as leverage point to increase footprint of AnteoBind in key accounts.
- Use raw material positioning to leverage into services opportunities.
- Continued focus on development of AnteoBind activated particle products.



Assay Services

- Approach market from a "problem solving" perspective.
- Leverage ISO 13485 based QMS process platform.
- Leverage our own Assay Development success.
- Identify opportunities where speed to execution is paramount requiring rapid technical and documentation execution.
- Focus on generation of short-term cash flow.

AnteoTech

Questions

AnteoTech

Energy

Li ion Battery Market Update 2020

Li ion Battery market USD $Billions

Growing in excess of 9% CAGR



Source: Rechargeable Battery Market Main Trends 2017 – 2030 Avicenne Energy

Silicon Based Li ion Batteries are Forecast to Dominate from 2023 to 2035



Source: "The Solid-State Battery Roadmap", November 2017, Christopher Robinson, Lux Research

2020: ~0.3M metric tons **2030:** >1.4M metric tons

CAGR 34%



Source: Avicenne Energy 2020

Our Strategy for Energy Focuses on Leveraging IP

Enhanced Li ion Battery

Become a materials supplier to producers of enhanced Lithium ion anodes.

Develop applications for the enhancement of silicon composites and binder systems.

International collaborations to support the development of silicon composites and binder additives.

AnteoCoat™, AnteoX™, AnteoLink™

Commercialisation roadmap at anode coating level

Cross Linked Additives
1st product – Manufacture and supply.

Advanced binder
2nd product – Manufacture and partnership hybrid model.



Silicon active materials
3rd product – Partnering for manufacturing and distribution.



Silicon anode system
4th product – Provide licenses to anode system.



VALUE/RETURN

TIME/COMPLEXITY

$/Wh
Cheaper Li ion battery

Wh/L
Smaller Li ion battery

Wh/kg
Lighter Li ion battery

Energy Business Collaborator Landscape

7 collaborators engaged with silicon composite project

6 collaborators engaged with cross-linker additive project

Collaborator ID	Company type
1	Battery materials and component manufacturer
2	Battery materials manufacturer (micro-silicon)
3	Battery materials and component manufacturer
4	Surface coating company and equipment manufacturer
5	Chemical company (silicon)
6	Chemical company (binders)
7	Battery materials manufacturer (nano-silicon)
8	Diversified electronics and chemical manufacturer
9	Battery manufacturer (portable electronics)

Energy Division – Achievements This Year

Industry network

- Business development initiative triples partner network from 3 to 9.
- 6 collaborators engaged.
- with cross-linker additive project.
- 7 collaborators engaged with silicon composite project.

Cross-linker additive and adv. binder



- Cross-linker additive (CLA) concept developed.
- CLA project firmly established and 1st gen CLA samples shipped.
- Positive results from CLA Testing against off the shelf binders and proprietary binders.
- Demonstrated up to 21% improvement in capacity for specific binder chemistries and anode configurations.

Silicon active materials



- Two samples of 1st gen composite successfully evaluated by partners.
- 2nd gen silicon composite development targeting cycling stability commenced.
- Independently validated particle specifications and capacity attributes of 1st gen composites.
- 2nd gen composite developed with improved electrochemical performance.

2020/2021 Energy Development Program

Q2 20/21 | **Q3** 20/21 | **Q4** 20/21 | **Q1** 21/22

Cross-linker additive and adv. binder



- Matching of CLAs with specific binder chemistries of collaborators.
- Fine-tune CLA properties and facilitate process integration with collaborators.
- Progress relationship to commercial level and prepare for low volume CLA supply.

Silicon active materials



- Refine composite structure/composition and enhance cycling stability.
- Supply 2nd generation composite to collaborators for testing and validation.
- Evaluate feasibility and business case for protective coatings on silicon active materials.

Silicon anode system



- First silicon composite and CLA/binder anode prototype developed.
- Evaluate feasibility and business case for a limited capacity micro-silicon anode system.
- Demonstration of anode system targeting >800mAh/g in full cell.

AnteoTech

Summary

Focus Objectives for the Next 12 Months

- Commercialise the first Point of Care assay – COVID-19 Antigen Rapid Test.
- Capitalise on the pipeline of opportunities that surround our capability and profile in the PoC market and in the vaccine industry.
- Increase sales from Assay Development, Assay Services and Raw Materials products.
- Commercialisation of Binder Additive (AnteoX) with focus on leveraging current collaboration network.
- Development focus on silicon active materials to align with market trends for low cost, stable, high performance anodes.

AnteoTech

Questions

www.anteotech.com